carfilzomib

an antineoplastic agent that inhibits the ubiquitin-proteasome pathway

Also Known As:

(2S)-N-((1S)-1-benzyl-2-(((1S)-3-methyl-1-(((2R)-2-methyloxiran-2-yl)carbonyl)butyl)amino)-2-oxoethyl)-4-methyl-2-(((2S)-2-((morpholin-4-ylacetyl)amino)-4-phenylbutanoyl)amino)pentanamide; Kyprolis; PR-171; PR171

Networked: 810 relevant articles (103 outcomes, 220 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Oligopeptides: 519
    - carfilzomib: 810

Experts

1.	Moreau, Philippe: 35 articles (10/2022 - 04/2014)
2.	Dimopoulos, Meletios A: 32 articles (06/2022 - 01/2015)
3.	Niesvizky, Ruben: 24 articles (12/2021 - 01/2013)
4.	Vij, Ravi: 22 articles (05/2021 - 06/2011)
5.	Landgren, Ola: 20 articles (10/2022 - 09/2015)
6.	Siegel, David S: 20 articles (01/2021 - 06/2012)
7.	Jakubowiak, Andrzej J: 19 articles (10/2022 - 06/2012)
8.	Orlowski, Robert Z: 19 articles (11/2021 - 11/2007)
9.	Ludwig, Heinz: 17 articles (11/2020 - 09/2012)
10.	Weisel, Katja: 16 articles (01/2022 - 01/2016)

Related Diseases

1.	Multiple Myeloma 01/01/2018 - "Once weekly carfilzomib appears safe and more effective with a convenient dosing regimen versus the twice weekly schedule for the treatment of patients with relapsed and refractory multiple myeloma. " 08/01/2022 - "Conclusion: Carfilzomib was found to be a safe and effective treatment for relapsed or refractory multiple myeloma in Japanese patients. " 08/07/2014 - "Standard carfilzomib (20 mg/m(2) cycle 1, 27 mg/m(2) thereafter; 2- to 10-minute infusion) is safe and effective in relapsed or refractory multiple myeloma (R/RMM). " 01/01/2012 - "Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma." 10/01/2016 - "Efficacy of carfilzomib in the treatment of relapsed and (or) refractory multiple myeloma: a meta-analysis of data from clinical trials."
2.	Neoplasms (Cancer) 12/28/2014 - "In vivo, liposomal carfilzomib demonstrated significant tumor growth inhibition and dramatically reduced overall systemic toxicity compared to free carfilzomib. " 01/01/2017 - "This study evaluated pharmacokinetics (PK) and safety of carfilzomib in patients with relapsed or progressive advanced malignancies and varying degrees of impaired hepatic function. " 01/01/2017 - "Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study." 10/01/2013 - "A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors." 11/23/2023 - "Research conducted in xenograft models demonstrates that ATF3 mediates the anti-tumor activity of Carfilzomib. "
3.	Hematologic Neoplasms (Hematological Malignancy) 11/15/2009 - "In a phase 1 trial evaluating the safety and efficacy of carfilzomib in relapsed or refractory hematologic malignancies, eight dose groups of three to six patients received 5 consecutive days of carfilzomib i.v. push at doses of 1.2, 2.4, 4, 6, 8.4, 11, 15, and 20 mg/m2 within 14-day cycles. " 12/01/2018 - "Our data provide pre-clinical information that can be incorporated into future early-phase clinical trials for the assessment of carfilzomib as a treatment for children with refractory hematological malignancies." 09/01/2012 - "The objectives of this phase I study were to establish the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of escalating doses of carfilzomib in patients with relapsed or refractory hematologic malignancies. " 05/01/2011 - "In clinical studies carfilzomib has demonstrated substantial antitumor activity in hematologic malignancies while exhibiting a well-tolerated side-effect profile. " 07/01/2007 - "These studies show the tolerability, efficacy, and dosing flexibility of PR-171 and provide validation for the clinical testing of PR-171 in the treatment of hematologic malignancies using dose-intensive schedules."
4.	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 11/01/2013 - "In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome." 01/01/2019 - "A phase II study of carfilzomib in the treatment of relapsed/refractory mantle cell lymphoma." 06/01/2019 - "[Effect of Carfilzomib on Proliferation and Apoptosis of Mantle Cell Lymphoma Cells]." 01/01/2017 - "Carfilzomib Inhibits Constitutive NF-κB Activation in Mantle Cell Lymphoma B Cells and Leads to the Induction of Apoptosis." 01/01/2020 - "A phase I study of carfilzomib in combination with ibrutinib for relapsed refractory mantle cell lymphoma."
5.	Cardiotoxicity 01/01/2022 - "While they have demonstrated efficacy and revolutionized treatment of MM, carfilzomib and other PI's are associated with cardiotoxicities." 01/01/2022 - "The purpose of this study is to characterize the cardiotoxicity of carfilzomib with respect to other PIs and all classes of medications using the US Food and Drug Administration Adverse Events Reporting System (FAERS) database and to define the observed cardiotoxicity profile. " 01/01/2022 - "No prior study has compared the cardiotoxicity of carfilzomib against other PI's and all other classes of medications. " 01/01/2018 - "Prospective trials evaluating carfilzomib in RRMM patients with adequate data on cardiac toxicities were included for analysis. " 01/01/2023 - "There is a need for well-designed prospective studies enrolling a diverse population to investigate potential interventions to prevent carfilzomib-associated cardiotoxicity."

Related Drugs and Biologics

1.	Proteasome Inhibitors
2.	Bortezomib (Velcade)
3.	Dexamethasone (Maxidex)
4.	Lenalidomide (CC 5013)
5.	pomalidomide
6.	isatuximab
7.	Proteasome Endopeptidase Complex (Proteasome)
8.	Thalidomide (Thalomid)
9.	daratumumab
10.	Cyclophosphamide (Cytoxan)

Related Therapies and Procedures

1.	Therapeutics
2.	Stem Cell Transplantation
3.	Drug Therapy (Chemotherapy)
4.	Renal Dialysis (Hemodialysis)
5.	Salvage Therapy